Compare Hubbell (HUBB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hubbell vs Organon & Co. Common Stock — how do they compare? Hubbell trades at $469.9 (market cap $25.25B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Hubbell is far larger — about 7× Organon & Co. Common Stock's market cap, and Hubbell pays the higher dividend (1.19%). Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| HUBB | OGN | |
|---|---|---|
Market Cap | $25.25B | $3.62B |
Volume | 443,319 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $557.85 | $13.81 |
52-Week Low | $407.36 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.41B | $11.04B |
Dividend Yield | 1.19% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hubbell Incorporated (HUBB) trades at $477.93, up 0.82% with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $4.73 vs. $4.71 expected, Q1 2026: $3.93 vs. $3.87, Q2 2026: $5.52 vs. $5.39) and robust profitability (net margin 14.49%, ROE 24.34%). Recent news highlights grid modernization opportunities and institutional buying interest from Bank of America and BNY Mellon.
Hubbell presents a favorable outlook with analyst consensus price target of $560.50 (17% upside) and strong institutional support. Key risks include integration challenges from recent acquisitions and dependence on utility spending cycles. The Q3 2026 earnings report on October 27 will be crucial for validating growth trajectory amid electrification demand.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
